The functional antagonist Met-RANTES: a modified agonist that induces differential CCR5 trafficking

• Autorzy: Kiss D L , Longden J. , Fechner G.A. , Avery V.M.
• Języki publikacji: EN

Abstrakty

EN

CC chemokine receptor 5 (CCR5) is a pro-inflammatory chemokine receptor that is expressed on cells of the immune system, and specializes in cell migration in response to inflammation and tissue damage. Due to its key role in cell communication and migration, this receptor is involved in various inflammatory and autoimmune diseases, in addition to HIV infection. Met-RANTES is a modified CCR5 ligand that has previously been shown to antagonize CCR5 activation and function in response to its natural ligands in vitro. In vivo, Met-RANTES is able to reduce inflammation in models of induced inflammatory and autoimmune diseases. However, due to the fact that Met-RANTES is also capable of partial agonist activity regarding receptor signaling and internalization, it is clear that Met-RANTES does not function as a conventional receptor antagonist. To further elucidate the effect of Met-RANTES on CCR5, receptor trafficking was investigated in a CHO-CCR5-GFP cell line using the Opera confocal plate reader. The internalization response of CCR5 was quantified, and showed that Met-RANTES internalized CCR5 in a slower, less potent manner than the agonists CCL3 and CCL5. Fluorescent organelle labeling and live cell imaging showed CCL3 and CCL5 caused CCR5 to traffic through sorting endosomes, recycling endosomes and the Golgi apparatus. In contrast, Met-RANTES caused CCR5 to traffic through sorting endosomes and the Golgi apparatus in a manner that was independent of recycling endosomes. As receptor trafficking impacts on cell surface expression and the ability of the receptor to respond to more ligand, this information may indicate an alternative regulation of CCR5 by Met-RANTES that allows the modified ligand to reduce inflammation through stimulation of a pro-inflammatory receptor.

Słowa kluczowe

EN

functional antagonist; modified agonist; CCR5 trafficking; chemokine receptor; cell type; G protein coupled receptor; human immunodeficiency virus zob.HIV; HIV; T cell; monocyte; dendritic cell; central nervous system

• Wydawca: -
• Czasopismo: Cellular and Molecular Biology Letters
• Rocznik: 2009
• Tom: 14
• Numer: 4
• Opis fizyczny: p.537-547,fig.,ref.

Twórcy

autor

Kiss D L

• Griffith University, Don Young Road, Nathan, QLD, 4111, Australia

autor

Longden J.

autor

Fechner G.A.

autor

Avery V.M.

Bibliografia

• 1. D'Ambrosio, D., Panina-Bordignon, P. and Sinigaglia, F. Chemokine receptors in inflammation: an overview. J. Immunol. Methods 273 (2003) 3-13.
• 2. Mueller, A. and Strange, P.G. Molecule in focus: the chemokine receptor CCR5. Int. J. Biochem. Cell. Biol. 26 (2003) 35-38.
• 3. Samson, M., Labbe, O., Mollereau, C., Vassart, G. and Parmentier, M. Molecular cloning and functional expression of a new human CCchemokine receptor gene. Biochemistry 35 (1996) 3362-3367.
• 4. Blanpain, C., Migeotte, I., Lee, B., Vakili, J., Doranz, B.J., Govaerts, C., Vassart, G., Doms, R.W. and Parmentier, M. CCR5 binds multiple CCchemokines: MCP-3 acts as a natural antagonist. Blood 94 (1999) 1899-1905.
• 5. Alkhatib, G., Combadiere, C., Broder, C., Feng, Y., Kennedy, P., Murphy, P. and Berger, E. CC CKR5: A RANTES, MIP-1α, MIP1β receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 272 (1996) 1955-1958.
• 6. Ben-Baruch, A. The multifaceted role of chemokines in malignancy. Cancer Metastasis Rev. 25 (2006) 357-371.
• 7. Proudfoot, A.E., Power, C.A., Hoogewerf, A.J., Montjovent, M., Borlat, F., Offords, R. and Wells, T. Extension of recombinant human RANTES by the retention of the initiating methionine produces a potent antagonist. J. Biol. Chem. 271 (1996) 2599-2603.
• 8. Mack, M., Luckow, B., Nelson, P., Cjhak, J., Simmons, G., Clapham, P., Signoret, N., Marsh, M., Stangassinger, M., Borlat, F., Wells, T., Schlöndorff, D. and Proudfoot, A. Aminooxypentane-RANTES induces CCR5 internalization but inhibits recycling: A novel inhibitory mechanism of HIV infectivity. J. Exp. Med. 187 (1998) 1215-1224.
• 9. Vila-Coro, A., Mellado, M., MartinDeAna, A., Martinez, C. and RodriguezFrade, J. Characterization of RANTES and aminooxypentane-RANTES triggered desensitizaion signals reveals differnces in recuitment of G protein coupled receptor complex. J. Immunol. 163 (1999) 3037-3044.
• 10. Elsner, J., Petering, H., Höchstetter, R., Kimmig, D., Wells, T.N., Kapp, A. and Proudfoot A.E. The CC chemokine antagonist Met-RANTES inhibits eosinophil effector functions through chemokine receptors CCR1 and CCR3. Eur. J. Immunol. 27 (1997) 2892-2898.
• 11. Olbrich, H., Proudfoot, A.E. and Oppermann, M. Chemokine-induced phosphorylation of CC chemokine receptor 5 (CCR5). J. Leukoc. Biol. 65 (1999) 281-285.
• 12. Gröne, H.J., Weber, C., Weber, K.S., Gröne, E.F., Rabelink, T., Klier, C.M., Wells, T.N., Proudfood, A.E., Schlöndorff, D. and Nelson, P.J. MetRANTES reduces vascular and tubular damage during acute renal transplant rejection: blocking monocyte arrest and recruitment. FASEB J. 13 (1999) 1371-1383.
• 13. Plater-Zyberk, C., Hoogewerf, A.J., Proudfoot, A.E., Power, C.A. and Wells, T.N. Effect of CC chemokine receptor antagonist on collagen induced arthritis in DBA/1 mice. Immunol. Lett. 57 (1997) 117-120.
• 14. Ajuebor, M.N., Hogaboam, C.M., Kunkel, S.L., Proudfoot, A.E. and Wallace, J.L. The chemokine RANTES is a crucial mediator of the progression from acute to chronic colitis in the rat. J. Immunol. 166 (2001) 552-558.
• 15. Chvatchko, Y., Proudfoot, A.E., Buser, R., Juillard, P., Alouani, S., KoscoVilbois, M., Coyle, A.J., Nibbs, R.J., Graham, G., Offord, R.E. and Wells, T.N. Inhibition of airway inflammation by amino-terminally modified RANTES/CC chemokine ligand 5 analogues is not mediated through CCR3. J. Immunol. 171 (2003) 5498-5506.
• 16. Wong, M., Uddin, S., Majchrzak, B., Huynh, T., Proudfoot, A.E., Platanias, L.C. and Fish, E.N. Rantes activates Jak2 and Jak3 to regulate engagement of multiple signaling pathways in T cells. J. Biol. Chem. 276 (2001) 11427-11431.
• 17. Longden, J., Cooke, E.L. and Hill, S.J. Effect of CCR5 receptor antagonists on endocytosis of the human CCR5 receptor in CHO-K1 cells. Br. J. Pharmacol. 153 (2008) 1513-1527.
• 18. Mukherjee, S., Ghosh, R.N. and Maxfield, F.R. Endocytosis. Physiol. Rev. 77 (1997) 759-803.
• 19. Signoret, N., Hewlett, L., Wavre, S., Pelchen-Matthews, A., Oppermann, M. and Marsh, M. Agonist-induced endocytosis of the CC chemokine receptor 5 is clathrin dependent. Mol. Cell. Biol. 16 (2005) 902-917.
• 20. Pagano, R.E., Martin, O.C., Kang, H.C. and Haugland, R.P. A novel fluorescent ceramide analogue for studying membrane traffic in animal cells: accumulation at the Golgi apparatus results in altered spectral properties of the sphingolipid precursor. J. Cell. Biol. 113 (1991) 1267-1279.
• 21. Signoret, N., Pelchen-Matthews, A., Mack, M., Proudfoot, A.E. and Marsh, M. Endocytosis and recycling of the HIV coreceptor CCR5. J. Cell. Biol. 121 (2000) 1281-1293.
• 22. Mueller, A., Kelly, E. and Strange, P.G. Pathways for internalization and recycling of the chemokine receptor CCR5. Blood 99 (2002) 785-791.
• 23. Venkatesan, S., Rose, J.J., Lodge, R., Murphy, P.M. and Foley, J.F. Distinct mechanisms of agonist-induced endocytosis for human chemokine receptors CCR5 and CXCR4. Mol. Biol. Cell. 14 (2003) 3305-3324.
• 24. Maxfield, F.R. and McGraw, T.E. Endocytic recycling. Nat. Rev. Mol. Cell. Biol. 5 (2004) 121-132.
• 25. Murphy, P.M., Baggiolini, M., Charo, I.F., Heber, C.A., Horuk, R., Matsushima, K., Miller, L.H., Oppenheim, J.J. and Power, C.A. International union of pharmacology XXII nomenclature for chemokine receptors. Pharm. Rev. 52 (2000) 145-176.
• 26. Oppermann, M. Chemokine receptor CCR5: insights into structure, function and regulation. Cell. Signal. 16 (2004) 1201-1210.